Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Retained Earnings: 2011-2024

Historic Retained Earnings for Niagen Bioscience (NAGE) over the last 11 years, with Dec 2024 value amounting to -$181.9 million.

  • Niagen Bioscience's Retained Earnings rose 10.80% to -$168.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$168.7 million, marking a year-over-year increase of 10.80%. This contributed to the annual value of -$181.9 million for FY2024, which is 4.49% up from last year.
  • Per Niagen Bioscience's latest filing, its Retained Earnings stood at -$181.9 million for FY2024, which was up 4.49% from -$190.5 million recorded in FY2023.
  • Over the past 5 years, Niagen Bioscience's Retained Earnings peaked at -$141.8 million during FY2020, and registered a low of -$190.5 million during FY2023.
  • Moreover, its 3-year median value for Retained Earnings was -$185.5 million (2022), whereas its average is -$186.0 million.
  • As far as peak fluctuations go, Niagen Bioscience's Retained Earnings fell by 19.13% in 2021, and later grew by 4.49% in 2024.
  • Yearly analysis of 5 years shows Niagen Bioscience's Retained Earnings stood at -$141.8 million in 2020, then declined by 19.13% to -$169.0 million in 2021, then decreased by 9.79% to -$185.5 million in 2022, then dropped by 2.68% to -$190.5 million in 2023, then climbed by 4.49% to -$181.9 million in 2024.